Jian ZHANG

Dr. Jian ZHANG


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JZJian ZHANG
Jian ZHANG
JRJianwei Ren
Jianwei Ren
JWJiamin Wei
Jiamin Wei
CCCharing Ching-Ning Chong
Charing Ching-Ning Chong
DYdongjie yang
dongjie yang
PLPaul B. S. Lai
Paul B. S. Lai
The role of estrogen receptor alpha (ERa), estrogen receptor beta (ERb) and ERa36 signaling in hepatocellular carcinoma (HCC) is not fully addressed. In this study, three cohorts were included: (i) primary HCC patients (N = 76, cohort P), (ii) colorectal liver metastasis (mCRC) (N = 32, cohort S), and (iii) HCC from The Cancer Genome Atlas (TCGA) (N = 121). The levels of ERa36 and wtER36 were measured and their correlation with clinicopathologic features was determined. WtERa was downregulated and that ERa36 was upregulated in tumor tissues in both cohort P and TCGA data set. ERa36 was downregulated in tumor tissues in cohort S. In cohort P, wtERa was differentially expressed in gender (P < 0.000), age (P = 0.004), tumor number (P = 0.043), tumor size (P = 0.002), intrahepatic recurrence (P = 0.054). ERa36 was unequally expressed in different non-tumor liver status (P = 0.040). WtERa was negatively associated with overall survival (OS) and disease free survival (DFS) in cohort P. Compared with non-tumor tissues, the expression of ERa36 was increased in primary HCC but decreased in secondary HCC, showing opposite expression patterns of ERa36 between primary HCC and secondary HCC. Primary HCC is associated with the decreased WtERa but increased ERa36. The expression pattern of ERa36 is different between primary HCC and secondary HCC, as the former with the increased ERa36 but the latter with the decreased ERa36. Therefore, the expression of ERa36 may be used to differentiate the primary HCC and the secondary one.

20 December 2005 in Pediatric Allergy and Immunology
Verified
Journal Article
Open access
PDF file
JZJian ZHANG
Jian ZHANG
OMOhsuke Migita
Ohsuke Migita
MKMinori Koga
Minori Koga
MSMasanao Shibasaki
Masanao Shibasaki
TATadao Arinami
Tadao Arinami
ENEmiko Noguchi
Emiko Noguchi
Pharmacologic studies have revealed that cysteinyl leukotrienes (CYSLTs) act through two receptors, cysteinyl leukotriene receptor 1 (CYSLTR1) and CYSLTR2. CYSLTR1 antagonists are widely used to treat asthma and rhinitis. In this study, we characterized the genomic structure and transcriptional regulation of CYSLTR1 and examined associations between CYSLTR1 polymorphisms and asthma/rhinitis. The experiment of rapid amplification of cDNA end revealed that CYSLTR1 contains three exons and that the entire open reading frame is located in exon 3. Reverse transcriptase‐polymerase chain reaction showed that there were multiple splice variants of CYSLTR1 and that the transcript expression patterns differed from tissues and cell types. The promoter region of CYSLTR1 is from −665 to −30 bp relative to the transcription start site. We identified four polymorphisms (c.‐618‐434T/C, c.‐618‐275C/A, c.‐618‐136G/A, and 927C/T), and transmission disequilibrium tests revealed that none of these polymorphisms was associated with the development of asthma/rhinitis. However, the TCG and CAA haplotypes in the promoter region caused different transcriptional activity. Our findings indicate that CYSLTR1 polymorphisms are not likely to be involved in the development of asthma/rhinitis, but it is possible that these polymorphisms could influence drug responses in individuals with atopic diseases.

4 March 2020 in Epigenomics
Verified
Journal Article
Closed access
JZJian ZHANG
Jian ZHANG
JWJiamin Wei
Jiamin Wei
ZWZhixiong Wang
Zhixiong Wang
YFYun Feng
Yun Feng
ZWZhewei Wei
Zhewei Wei
DYdongjie yang
dongjie yang
Aim: Altered long noncoding RNA (lncRNA) and mRNA is vital in the progression from Helicobacter pylori (H. pylori, HP) infection to gastric cancer (GC) and mucosa-associated lymphoid tissue (MALT) ...

24 April 2021 in Cells
Verified
Journal Article
Open access
PDF file
WCWei Chen
Wei Chen
JZJian ZHANG
Jian ZHANG
HFHuaFeng Fu
HuaFeng Fu
XHXun Hou
Xun Hou
QSQiao Su
Qiao Su
DYdongjie yang
dongjie yang
Gastric cancer is the third leading cause of cancer death worldwide. In this study, we tried to clarify the function of KLF5 in gastric cancer. Copy number variation (CNV) and the expression of KLF5 were interrogated in public datasets. The clinical significance of KLF5 amplification and gene expression in gastric cancer were evaluated. The function of KLF5 in cell proliferation was studied in gastric cancer cell lines and organoids. We found that KLF5 amplification mainly occurred in the chromosome instable tumors (CIN) and was significantly associated with TP53 mutation. In addition, higher KLF5 expression correlated with more locally invasive gastric cancer and higher T stage. Next, a KLF5 gene expression signature was curated. The genes in the signature were involved in cell development, cell cycle regulation, cell death, suggesting potential roles played by KLF5. Functional studies using siRNAs revealed that KLF5 was essential for the proliferation of gastric cancer cells. Finally, using gastric organoid models, we revealed that the proliferation of organoids was significantly inhibited after the down regulation of KLF5. Our study revealed that KLF5 was amplified and over-expressed in gastric cancer, and it may play an oncogene-like role in gastric cancer by supporting cell proliferation.

4 June 2019 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
WSWei-Kun Shi
Wei-Kun Shi
XZXin-Hua Zhang
Xin-Hua Zhang
JZJian ZHANG
Jian ZHANG
MYMiao Yu
Miao Yu
YYYu-Jie Yuan
Yu-Jie Yuan
ZWZhe-Wei Wei
Zhe-Wei Wei
Prognostic nutritional index was found to be correlated with prognosis in GISTs before and after propensity score matching and its incorporation improved the prognostic stratification of NIH risk criteria.

17 August 2022 in Cancers
Verified
Journal Article
Open access
PDF file
HFHuafeng Fu
Huafeng Fu
JZJian ZHANG
Jian ZHANG
QCQinbo Cai
Qinbo Cai
YHYulong He
Yulong He
DYdongjie yang
dongjie yang
The atrial natriuretic peptide (ANP), a cardiovascular hormone, plays a pivotal role in the homeostatic control of blood pressure, electrolytes, and water balance and is approved to treat congestive heart failure. In addition, there is a growing realization that ANPs might be related to immune response and tumor growth. The anti-inflammatory and immune-modulatory effects of ANPs in the tissue microenvironment are mediated through autocrine or paracrine mechanisms, which further suppress tumorigenesis. In cancers, ANPs show anti-proliferative effects through several molecular pathways. Furthermore, ANPs attenuate the side effects of cancer therapy. Therefore, ANPs act on several hallmarks of cancer, such as inflammation, angiogenesis, sustained tumor growth, and metastasis. In this review, we summarized the contributions of ANPs in diverse aspects of the immune system and the molecular mechanisms underlying the anti-cancer effects of ANPs.